Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the molecular virology of hepatitis C virus (HCV) and targets of pharmacologic intervention
- Recount the current understanding of resistance mutations with new HCV therapies
- Discuss recent efficacy and safety data from phase II or later studies of investigational agents for HCV (including targeted therapies, novel interferons, and potential interferon enhancers such as nitazoxanide)
- Compare the potential impact that investigational agents may have on the management of patients with HCV (including the role of pegylated interferon and ribavirin)
Topics covered include:
- Introduction
- Novel Interferons
- Alternatives to Ribavirin
- Overview of the HCV Lifecycle
- Inhibitors of HCV Entry and Fusion
- Inhibitors of HCV Polyprotein Translation
- Inhibitors of HCV Polyprotein Processing
- Inhibitors of HCV Replication
- Inhibitors of HCV Assembly and Release
- Other Investigational Agents
- Conclusions
Abstract